Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Asymptomatic Aortic Stenosis: A Complex Decision

Asymptomatic severe aortic stenosis continues to pose a significant challenge when it comes to clinical decision-making, often due to the difficulty in identifying symptoms. When this condition is symptomatic or oligosymptomatic, it is associated with increased rates of hospitalization and mortality.

While current guidelines recommend valve replacement in cases of impaired ventricular function, available reports are not definitive regarding its implementation.

Researchers conducted a meta-analysis that included four randomized studies (EARLY TAVR, EVoLVeD, AVATAR, and RECOVERY), with a total of 1427 patients. Of these, 719 underwent early aortic valve replacement through surgical or transcatheter aortic valve replacement (SAVR or TAVR), while the rest underwent clinical follow-up (CF) alone.

Read also: 1-Year Outcomes of US TAVR Registry with 5th Generation Balloon Expandable Valves.

With an average follow-up of four years, TAVR demonstrated a significant reduction in the rates of hospitalization due to cardiovascular causes or heart failure (combined rate: 14.6% vs. 31.9%; hazard ratio [HR]: 0.40; 95% confidence interval [CI]: 0.30–0.53; I² = 4%; p < 0.01) and in the incidence of stroke (combined rate: 4.5% vs. 7.2%; HR: 0.62; 95% CI: 0.40–0.97; I² = 0%; p = 0.03). However, there were no significant differences in all-cause mortality (combined rate: 9.7% vs. 13.7%; HR: 0.68; 95% CI: 0.40–1.17; I² = 61%; p = 0.17) or cardiovascular mortality (combined rate: 5.1% vs. 8.3%; HR: 0.67; 95% CI: 0.35–1.29; I² = 50%; p = 0.23). It is worth noting that the studies analyzed were highly heterogeneous.

Conclusion

In this meta-analysis of four randomized studies, early aortic valve replacement was associated with a significant reduction in hospitalization rates due to cardiovascular causes or heart failure, as well as in the incidence of stroke. However, there were no differences in all-cause mortality or cardiovascular mortality compared to clinical follow-up.

Original Title: Aortic Valve Replacement vs Clinical Surveillance in Asymptomatic Severe Aortic Stenosis: A Systematic Review and Meta-Analysis. 

Reference: Philippe Généreux, et al. JACC article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...